Physician profile
James J Lyons
NPI 1104096544
$210,222.07
in general payments reported to CMS, 2019-2025
10 companies · $56K in 2025
The $56K reported for 2025 was more than what 99% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $17K · 2021: $36K · 2022: $15K · 2023: $13K · 2024: $59K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $129K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $128,859.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $128,859.71 | 2023-2025 | |
| Csl Behring | $80,952.73 | 2019-2022 | |
| Abbott Laboratories | $101.62 | 2019 | |
| Novo Nordisk INC | $87.92 | 2021-2022 | |
| Lilly USA, LLC | $85.09 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $45.23 | 2021 | |
| Merck Sharp & Dohme LLC | $33.67 | 2020-2021 | |
| Amgen INC. | $25.92 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.90 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.28 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.